These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38985597)
21. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium. Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771 [TBL] [Abstract][Full Text] [Related]
22. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705 [TBL] [Abstract][Full Text] [Related]
23. Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes. Gheorghiade M; Sabbah HN Am J Cardiol; 2007 Jan; 99(2A):1A-3A. PubMed ID: 17239700 [No Abstract] [Full Text] [Related]
24. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704 [TBL] [Abstract][Full Text] [Related]
25. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. Carubelli V; Zhang Y; Metra M; Lombardi C; Felker GM; Filippatos G; O'Connor CM; Teerlink JR; Simmons P; Segal R; Malfatto G; La Rovere MT; Li D; Han X; Yuan Z; Yao Y; Li B; Lau LF; Bianchi G; Zhang J; Eur J Heart Fail; 2020 Sep; 22(9):1684-1693. PubMed ID: 31975496 [TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M; Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261 [TBL] [Abstract][Full Text] [Related]
27. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters. Lo Giudice P; Mattera GG; Gagnol JP; Borsini F Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411 [TBL] [Abstract][Full Text] [Related]
28. Weighing in on heart failure: the role of SERCA2a SUMOylation. Schwartz RJ; Yeh ET Circ Res; 2012 Jan; 110(2):198-9. PubMed ID: 22267837 [No Abstract] [Full Text] [Related]
29. Role of SIRT1 in Modulating Acetylation of the Sarco-Endoplasmic Reticulum Ca Gorski PA; Jang SP; Jeong D; Lee A; Lee P; Oh JG; Chepurko V; Yang DK; Kwak TH; Eom SH; Park ZY; Yoo YJ; Kim DH; Kook H; Sunagawa Y; Morimoto T; Hasegawa K; Sadoshima J; Vangheluwe P; Hajjar RJ; Park WJ; Kho C Circ Res; 2019 Apr; 124(9):e63-e80. PubMed ID: 30786847 [TBL] [Abstract][Full Text] [Related]
30. [Effects of Astragalus membranaccus on cardiac function and SERCA2a gene expression in myocardial tissues of rats with chronic heart failure]. Su D; Yan HR; Zhang BB; Wu DZ; Dai YL Zhong Yao Cai; 2009 Jan; 32(1):85-8. PubMed ID: 19445129 [TBL] [Abstract][Full Text] [Related]
31. CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Wang X; Ni L; Yang L; Duan Q; Chen C; Edin ML; Zeldin DC; Wang DW Mol Pharmacol; 2014 Jan; 85(1):105-15. PubMed ID: 24145329 [TBL] [Abstract][Full Text] [Related]
33. Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Campia U; Nodari S; Gheorghiade M Curr Heart Fail Rep; 2010 Sep; 7(3):100-9. PubMed ID: 20625945 [TBL] [Abstract][Full Text] [Related]
34. [Modification of sarco-endoplasmic reticulum Ca(2 +) -ATPase in the failing cardiomyocyte]. Ikeda Y Clin Calcium; 2013 Apr; 23(4):535-42. PubMed ID: 23545743 [TBL] [Abstract][Full Text] [Related]
35. Rg3 promotes the SUMOylation of SERCA2a and corrects cardiac dysfunction in heart failure. Liu Z; Bian X; Gao W; Su J; Ma C; Xiao X; Yu T; Zhang H; Liu X; Fan G Pharmacol Res; 2021 Oct; 172():105843. PubMed ID: 34428586 [TBL] [Abstract][Full Text] [Related]
36. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Kho C; Lee A; Jeong D; Oh JG; Gorski PA; Fish K; Sanchez R; DeVita RJ; Christensen G; Dahl R; Hajjar RJ Nat Commun; 2015 Jun; 6():7229. PubMed ID: 26068603 [TBL] [Abstract][Full Text] [Related]
37. [Expressions of SERCA2a and miR-25-3p/5p in myocardium of rats with heart failure and therapeutic effects of Xiefei Lishui recipe]. Wu JB; Ye XH; Xian SX; Dong MG Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2017 Feb; 33(2):146-150. PubMed ID: 29931923 [TBL] [Abstract][Full Text] [Related]
38. SERCA2a: a key protein in the Ca Zhihao L; Jingyu N; Lan L; Michael S; Rui G; Xiyun B; Xiaozhi L; Guanwei F Heart Fail Rev; 2020 May; 25(3):523-535. PubMed ID: 31701344 [TBL] [Abstract][Full Text] [Related]
39. Peptidyl-Prolyl Isomerase 1 Regulates Ca Sacchi V; Wang BJ; Kubli D; Martinez AS; Jin JK; Alvarez R; Hariharan N; Glembotski C; Uchida T; Malter JS; Yang Y; Gross P; Zhang C; Houser S; Rota M; Sussman MA J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29018025 [TBL] [Abstract][Full Text] [Related]
40. Improving cardiac Ca⁺² transport into the sarcoplasmic reticulum in heart failure: lessons from the ubiquitous SERCA2b Ca⁺² pump. Vangheluwe P; Wuytack F Biochem Soc Trans; 2011 Jun; 39(3):781-7. PubMed ID: 21599649 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]